Quantum Biopharma EBITDA per Share

What does Quantum Biopharma do? FSD Pharma Inc generates revenue through its Biotechnology segment, which develops drug candidates including Lucid-MS for neurodegenerative disorders, Lucid-PSYCH for mental health disorders, and UNBUZZD, a natural supplement targeting liver and brain function to alleviate alcohol effects. The Strategic Investments segment provides loans secured by residential or commercial real estate to generate returns and cash flow. The company's primary buyers are pharmaceutical researchers and investors in biotechnology, while real estate-backed loan recipients represent a secondary customer segment. Revenue streams are derived from both R&D progress and strategic investment returns. The Biotechnology segment focuses on advancing Lucid-MS, Lucid-PSYCH, and UNBUZZD through research and development, with Lucid-PSYCH targeting mental health applications and Lucid-MS addressing neurodegenerative conditions. UNBUZZD serves as a dietary supplement for alcohol recovery. Strategic Investments leverage real estate collateral to secure loans, creating a steady income stream from property-backed financing. These segments operate independently but contribute to the company's overall financial performance. FSD Pharma Inc's revenue model combines biopharmaceutical product development with real estate-secured lending. The Biotechnology segment's drug candidates attract biotech investors and pharmaceutical partners, while the Strategic Investments segment appeals to real estate investors seeking collateralized lending opportunities. Both segments operate under the company's dual focus on healthcare innovation and financial returns through secured lending. Quantum Biopharma is one of the most popular companies on Eulerpool.